Sustained treatment-free remission in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing Nilotinib versus Imatinib with switch to Nilotinib in absence of optimal response. SUSTRENIM Study – GIMEMA CML1415
Chronic myeloid leukaemia (CML) is a type of blood cancer that is usually managed with daily targeted tablets. This study compares two well-known drugs: imatinib (Glivec) and nilotinib (Tasigna). Some patients start directly on nilotinib, while others start on imatinib and only switch to nilotinib if their response is not strong enough. The main aim is to see which approach works best to lower leukaemia cells in the blood to tiny, undetectable amounts. When cancer levels drop this low for a long time, some patients can safely pause or stop taking their daily medication without the cancer returning. This is known as treatment-free remission. Researchers will follow participants for up to five years, monitoring their blood tests, side effects, and overall wellbeing to see if stopping tablets is safe, achievable, and long-lasting.
En un coup d'œil
De quoi parle cette étude ?
Chronic myeloid leukaemia (CML) is a slow-growing cancer of the white blood cells. In the past, people needed to take daily medication for the rest of their lives to keep it under control. Today, modern targeted tablets work so well that leukaemia cells can be reduced to barely detectable levels in the blood.
This study, known as the SUSTRENIM trial, compares two standard medicines: imatinib (Glivec) and nilotinib (Tasigna). Both drugs block a specific protein that tells leukaemia cells to grow. Researchers want to compare two ways of giving them: starting straight away with nilotinib, or starting with imatinib and switching to nilotinib only if the first drug does not clear the leukaemia quickly enough.
The primary goal is to find out which method gives patients a better chance of reaching a very deep response. If the cancer levels stay extremely low for a sustained period, doctors may invite patients to stop taking their daily tablets altogether under close supervision. This is called 'treatment-free remission', and it can give patients a break from daily medication and long-term side effects.
Over five years, doctors will monitor participants closely with regular blood tests. They will also look at how patients feel day-to-day, checking their quality of life and making sure any rising cancer levels are caught and treated immediately.
Points clés
- Compares two standard daily tablets (imatinib and nilotinib) for chronic myeloid leukaemia.
- Aims to see which drug approach best helps patients safely stop taking daily medication long-term.
- Open to adults aged 18 and over who have chronic phase CML.
- Involves regular blood tests over a five-year period to track cancer levels closely.
- Taking part is voluntary, and you can stop participating at any time.
Qui peut être éligible ?
This trial is open to adults aged 18 and older who have been diagnosed with chronic myeloid leukaemia (CML) in its earliest and most manageable stage, known as the chronic phase. Men and women can both take part.
To be eligible, your leukaemia must carry a specific genetic feature known as the BCR-ABL marker, which is standard for CML. You must also be able to take oral capsules each day and attend regular hospital appointments for check-ups and blood tests.
You may not be eligible if your leukaemia has progressed beyond the chronic phase or if you have already had extensive treatment for CML. Your hospital doctor will review your medical history and run tests to confirm whether this trial is safe and appropriate for you.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- I am aged 18 or older.
- I have been diagnosed with chronic myeloid leukaemia (CML) in the chronic phase.
- My leukaemia is confirmed to have the BCR-ABL marker.
- I am able to swallow daily capsules.
- I can attend regular hospital visits and blood tests over several years.
En quoi consiste la participation ?
If you take part, you will be prescribed daily capsules of either imatinib or nilotinib to take at home. If you start on imatinib and your routine tests show the leukaemia is not clearing quickly enough, your doctor will switch your prescription to nilotinib. You will visit the hospital regularly for check-ups, especially during the first two years. These visits involve physical checks, questionnaires about your daily wellbeing, and sensitive blood tests that measure exact leukaemia levels. If your cancer drops to very deep, undetectable levels and remains stable, your doctor may discuss pausing your medication. You will continue to be monitored closely for up to five years in total.
Risques et avantages potentiels
Emplacements (2)
- —Non vérifiéPays-Bas
- —Non vérifiéItalie
Questions fréquentes
What is treatment-free remission?
It means your leukaemia levels have dropped so low that you can safely stop taking daily medicine, while doctors keep a close eye on your blood to ensure the cancer stays away.
Are the study medicines experimental?
No. Both imatinib (Glivec) and nilotinib (Tasigna) are well-established, standard treatments already widely used for chronic myeloid leukaemia.
What happens if the leukaemia returns after I stop taking tablets?
Because you will have regular blood tests, any rise in leukaemia cells will be spotted early. If this happens, you restart your medication, which usually brings the cancer back under control quickly.
How often will I need to visit the hospital?
Visits are more frequent during the first year—often every few weeks or months—and become less frequent over time as your condition stabilises.
Puis-je quitter l'étude si je change d'avis ?
Yes. You can leave the trial at any point without giving a reason, and your medical team will continue to provide you with standard cancer care.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Intéressé à participer ?
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.